Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10836 |
CLK1-IN-1
|
CDK | Cell Cycle/Checkpoint |
CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM). | |||
T23897 |
CLK1/2-IN-3
CLK1/2 inhibitor 3,CLK1/2-inhibitor-3,CLK1/2 IN 3,CLK1/2IN3 |
CDK | Cell Cycle/Checkpoint |
CLK1/2-IN-3(Cpd-3) 是一种具有高效性和选择性的 CLK1 和 CLK2 抑制剂,抗增殖活性,抑制 CLK1、CLK2、SRPK1、SRPK2、SRPK3 的 的活性。CLK1/2-IN-3 可诱导核斑点扩大,可诱导S6K pre-mRNA选择性剪接和随后抑制多种癌细胞类型细胞生长。 | |||
T23896 |
CLK1/2-IN-1
CLK1/2 inhibitor 1,CLK1/2IN1,CLK1/2-inhibitor-1 |
||
CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2. | |||
T61543 | CLK1/4-IN-1 | ||
CLK1/4-IN-1 (compound 31) is a highly potent and selective inhibitor of Clk1 and Clk4, with IC50 values of 9.7 nM and 6.6 nM, respectively. It effectively inhibits the growth of T24 cancer cells, with a GI50 value of 1.1 μM. CLK1/4-IN-1 has shown promising potential as an anticancer research tool [1]. | |||
T73321 |
CLK1-IN-2
|
||
CLK1-IN-2 是代谢稳定的Clk1抑制剂。CLK1-IN-2 对 Clk1 具有选择性,IC50值为 1.7 nM。CLK1-IN-2 可用于肿瘤、杜氏肌营养不良症和病毒感染如HIV-1和流感的研究。 | |||
T60394 |
Haspin-IN-2
|
||
Haspin-IN-2 (compound 4) 是一种有效的选择性的 haspin 抑制剂,IC50为 50 nM。Haspin-IN-1 还抑制 CLK1和DYRK1A,IC50分别为 445 nM 和 917 nM。 | |||
T60477 | Haspin-IN-1 | ||
Haspin-IN-1 (compound 2a) 是一种haspin(单倍体生殖细胞特异性核蛋白激酶)抑制剂,IC50值为 119 nM。Haspin-IN-1 还抑制CLK1、DYRK1A 和 CDK9,IC50分别为 221 nM 、916.3 nM 和406.8 nM。Haspin-IN-1具有开发新型抗癌药物的潜力[1]。 | |||
T36684 | Ipivivint | ||
Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ip... |